Modifying the disease course
The following twelve (.pdf article) U.S. Food and Drug Administration (FDA)-approved disease-modifying agents (.pdf brochure) reduce disease activity and disease progression for many people with relapsing forms of MS, including relapsing-remitting MS, as well as secondary-progressive and progressive-relapsing MS in those people who continue to have relapses.
Following the treatment plan that you and your doctor have established is the best possible strategy for managing your MS:
MS relapses are caused by inflammation in the central nervous system that damages the myelin coating around nerve fibers. This damage slows or disrupts the transmission of nerve impulses and causes the symptoms of MS. Most relapses will gradually resolve without treatment.
For severe relapses (involving loss of vision, severe weakness or poor balance, for example), which interfere with a person’s mobility, safety or overall ability to function, most neurologists recommend treatment with corticosteroids. The most common treatment regimen is a three-to-five-day course of high-dose, intravenous corticosteroids to reduce inflammation and end the relapse more quickly. This regimen may or may not be followed with a slow taper of oral prednisone. Corticosteroids are not believed to have any long-term benefit on the disease. Medication options include:
High-dose intravenous Solu-Medrol® (methylprednisolone)
High-dose oral Deltasone® (prednisone)
H.P. Acthar Gel (ACTH) is an option for those who are unable to cope with the side effects of high-dose corticosteroids, have been treated unsuccessfully with corticosteroids, do not have access to intravenous therapy, or have trouble receiving medication intravenously because of difficulty accessing the veins.
A wide variety of medications are used to help manage the symptoms of MS. Below are common symptoms of MS and the medications used to treat those symptoms.